PriceTargets.com logo

RVL Pharmaceuticals - RVLP Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $2.50
  • Forecasted Upside: 2,786.84%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.09 As of 09/29/2023 01:00 AM ET
▲ +0.01 (13.05%)

This chart shows the closing price for RVLP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New RVL Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RVLP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RVLP

Analyst Price Target is $2.50
▲ +2,786.84% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for RVL Pharmaceuticals in the last 3 months. The average price target is $2.50, with a high forecast of $3.00 and a low forecast of $2.00. The average price target represents a 2,786.84% upside from the last price of $0.09.

This chart shows the closing price for RVLP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 3 investment analysts is to moderate buy stock in RVL Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/8/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/7/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/3/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/3/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/2/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/21/2023HC WainwrightLower TargetBuy ➝ Buy$4.00 ➝ $3.00Low
5/12/2023HC WainwrightLower Target$5.00 ➝ $4.00Low
5/1/2023BarclaysLower Target$3.00 ➝ $2.00Low
3/21/2023HC WainwrightReiterated RatingBuy$5.00Low
10/25/2022BarclaysLower TargetOverweight$4.00 ➝ $3.00Low
10/21/2022Jefferies Financial GroupReiterated RatingHold$2.50Low
4/5/2022BarclaysInitiated CoverageOverweight ➝ OverweightN/A
(Data available from 9/30/2018 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2023
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/2/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/1/2023
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/31/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
RVL Pharmaceuticals logo
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Read More

Today's Range

Now: $0.09
Low: $0.08
High: $0.13

50 Day Range

MA: $0.23
Low: $0.08
High: $0.50

52 Week Range

Now: $0.09
Low: $0.08
High: $2.42

Volume

190,285,456 shs

Average Volume

9,926,417 shs

Market Capitalization

$9.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15

Frequently Asked Questions

What sell-side analysts currently cover shares of RVL Pharmaceuticals?

The following sell-side analysts have issued stock ratings on RVL Pharmaceuticals in the last year: Barclays PLC, HC Wainwright, and Jefferies Financial Group Inc..
View the latest analyst ratings for RVLP.

What is the current price target for RVL Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for RVL Pharmaceuticals in the last year. Their average twelve-month price target is $2.50, suggesting a possible upside of 2,786.8%. HC Wainwright has the highest price target set, predicting RVLP will reach $3.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $2.00 for RVL Pharmaceuticals in the next year.
View the latest price targets for RVLP.

What is the current consensus analyst rating for RVL Pharmaceuticals?

RVL Pharmaceuticals currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RVLP.

What other companies compete with RVL Pharmaceuticals?

Other companies that are similar to RVL Pharmaceuticals include AcelRx Pharmaceuticals, Shuttle Pharmaceuticals, Lipella Pharmaceuticals, Apexigen and Guardion Health Sciences. Learn More about companies similar to RVL Pharmaceuticals.

How do I contact RVL Pharmaceuticals' investor relations team?

RVL Pharmaceuticals' physical mailing address is 400 Crossing Blvd, Bridgewater, New Jersey 08807-2863. The company's listed phone number is (908) 809-1300 and its investor relations email address is [email protected]. The official website for RVL Pharmaceuticals is www.osmotica.com. Learn More about contacing RVL Pharmaceuticals investor relations.